Multicenter Phase II Study of Axitinib in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AXIPAP
- 28 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.